Helix Biopharma Corp Stock Performance
HBP Stock | CAD 0.22 0.01 4.76% |
On a scale of 0 to 100, Helix BioPharma holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of -0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Helix BioPharma are expected to decrease at a much lower rate. During the bear market, Helix BioPharma is likely to outperform the market. Please check Helix BioPharma's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Helix BioPharma's current trending patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Helix BioPharma Corp are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Helix BioPharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Helix BioPharma Stock Price Passes Above 50-Day Moving Average of 0.19 - Defense World | 03/07/2024 |
2 | Helix BioPharma Completes 1.9M Private Placement - TipRanks.com - TipRanks | 04/08/2024 |
Begin Period Cash Flow | 3.3 M | |
Total Cashflows From Investing Activities | -5000.00 |
Helix |
Helix BioPharma Relative Risk vs. Return Landscape
If you would invest 20.00 in Helix BioPharma Corp on February 2, 2024 and sell it today you would earn a total of 2.00 from holding Helix BioPharma Corp or generate 10.0% return on investment over 90 days. Helix BioPharma Corp is generating 0.258% of daily returns assuming 4.5898% volatility of returns over the 90 days investment horizon. Simply put, 40% of all stocks have less volatile historical return distribution than Helix BioPharma, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
Risk |
Helix BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Helix BioPharma Corp, and traders can use it to determine the average amount a Helix BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0562
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | HBP | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
4.59 actual daily | 40 60% of assets are more volatile |
Expected Return
0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Helix BioPharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Helix BioPharma by adding it to a well-diversified portfolio.
Helix BioPharma Fundamentals Growth
Helix Stock prices reflect investors' perceptions of the future prospects and financial health of Helix BioPharma, and Helix BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Helix Stock performance.
Return On Equity | -12.06 | ||||
Return On Asset | -1.12 | ||||
Current Valuation | 46.03 M | ||||
Shares Outstanding | 229.44 M | ||||
Price To Earning | (7.09) X | ||||
Price To Book | 68.24 X | ||||
EBITDA | (5.98 M) | ||||
Net Income | (6.29 M) | ||||
Cash And Equivalents | 938 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 2.47 M | ||||
Current Ratio | 0.37 X | ||||
Book Value Per Share | 0 X | ||||
Cash Flow From Operations | (5.53 M) | ||||
Earnings Per Share | (0.03) X | ||||
Market Capitalization | 50.48 M | ||||
Total Asset | 1.03 M | ||||
Retained Earnings | (197.05 M) | ||||
Working Capital | (878 K) | ||||
About Helix BioPharma Performance
To evaluate Helix BioPharma Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Helix BioPharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Helix Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Helix BioPharma Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Helix's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 4.5 K | 4.7 K | |
Return On Tangible Assets | (7.03) | (6.68) | |
Return On Capital Employed | 6.69 | 6.35 | |
Return On Assets | (7.03) | (6.68) | |
Return On Equity | 6.71 | 6.37 |
Things to note about Helix BioPharma Corp performance evaluation
Checking the ongoing alerts about Helix BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Helix BioPharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
Helix BioPharma Corp had very high historical volatility over the last 90 days | |
Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
The company has accumulated 2.47 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
Net Loss for the year was (6.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Helix BioPharma Corp has accumulated about 938 K in cash with (5.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
Roughly 20.0% of the company shares are held by company insiders | |
Latest headline from news.google.com: Helix BioPharma Completes 1.9M Private Placement - TipRanks.com - TipRanks |
- Analyzing Helix BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Helix BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Helix BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Helix BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Helix BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Helix BioPharma's stock. These opinions can provide insight into Helix BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Helix Stock analysis
When running Helix BioPharma's price analysis, check to measure Helix BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helix BioPharma is operating at the current time. Most of Helix BioPharma's value examination focuses on studying past and present price action to predict the probability of Helix BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helix BioPharma's price. Additionally, you may evaluate how the addition of Helix BioPharma to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |